NCT07451769 Selective Activation of the Adrenomedullin Receptors in Migraine
| NCT ID | NCT07451769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Danish Headache Center |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-03-12 |
| Primary Completion | 2027-03-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2026-03-12 with a primary completion date of 2027-03-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent has been obtained prior to the initiation of any study-specific procedures. 2. Age ≥18 years at the time of screening. 3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and/or patient self-report, and diagnosed in accordance with the ICHD-3 criteria. Exclusion Criteria: 1. History of any other primary headache disorder, except for tension-type headache with \<5 headache days per month, based on ICHD-3 classification. 2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening. 3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening. 4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists. 5. Known risk of self-harm or harm to others, including a history of suicidal behavior. 6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity. 7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential. 8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period. 9. Evidence of current pregnancy or breastfeeding based on self-report or medical records. 10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07451769 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07451769 currently recruiting?
Yes, NCT07451769 is actively recruiting participants. Contact the research team at annette.maria.ellekaer.fuchs@regionh.dk for enrollment information.
Where is the NCT07451769 trial being conducted?
This trial is being conducted at Glostrup Municipality, Denmark.
Who is sponsoring the NCT07451769 clinical trial?
NCT07451769 is sponsored by Danish Headache Center. The trial plans to enroll 26 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.